跳至主要内容
临床试验/NCT07832045
NCT07832045招募中不适用

Endoscopic Ultrasound Guided Hepaticogastrostomy With or Without Antegrade Stenting for Palliation of Malignant Distal Biliary Obstruction: Randomized Controlled Trial

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2026年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
88
试验地点
1
主要终点
Recurrent biliary obstruction (RBO) rate

研究概览

简要总结

The purpose of this study is to compare the efficacy and safety between EUS-HGAS and EUS-HGS. We hypothesized that EUS-HGAS provides lower recurrent biliary obstruction (RBO) rate but with a comparable safety profile to EUS-HGS.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18 years or older with malignant distal biliary obstruction
  • Failed ERCP
  • The papilla is inaccessible owing to a surgically altered anatomy or gastric outlet obstruction

排除标准

  • Patients younger than 18 years old
  • Cancer infiltration of the gastric/duodenal wall within the planned puncture route
  • Patients with uncorrectable coagulopathy
  • Patients with unmanageable ascites
  • Patients with serious comorbidities that prohibited endoscopic management
  • Patients with pregnancy
  • Patients who cannot or refuse to provide informed consent

研究组 & 干预措施

HGS

Active Comparator

Endoscopic ultrasound guided hepaticogastrostomy

干预措施: HGS (Device)

HGAS

Experimental

Endoscopic ultrasound guided hepaticogastrostomy with antegrade stenting through the major papilla

干预措施: HGAS (Device)

结局指标

主要结局

Recurrent biliary obstruction (RBO) rate

时间窗: From enrollment to the end of follow-up up to 12 months

the proportion of participants experiencing RBO, defined by cholangitis, jaundice or findings of images, from index day of EUS-BD to the date of last follow-up

次要结局

  • Time to Recurrent Biliary Obstruction(From date of enrollment until the date of first documented recurrent biliary obstruction, date of death from any cause or date of last follow-up, whichever came first, assessed up to 12 months)
  • Tract dilation success(From the start of the EUS-BD to completion or failure of dilation, assessed on the day of the drainage procedure)
  • Final procedure success(From the start of the EUS-BD to completion or failure of stent deployment, assessed on the day of the drainage procedure)
  • Procedural duration(The time elapsed between puncture of the intrahepatic duct and completion of deployment of stent, assessed on the day of the drainage procedure.)
  • Clinical success(a decrease in bilirubin within 14 days to < 50 % of levels before EUS-BD)
  • Adverse events(From the day of procedure to the completion of follow-up up to 12 months)
  • Length of hospital stay after procedure(From the day of procedure to discharge, assessed up to 12 months)
  • Overall survival(Survival rate at the end of the follow-up period, assessed up to 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验